Abstracts tagged "ANCA and systemic vasculitides"

Abstract Number: 1674 • 2019 ACR/ARP Annual Meeting
Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience
Victor Pimentel-Quiroz¹, Alfredo Sánchez-Torres ², Eduardo Acevedo-Vásquez ³, Rocío-V. Gamboa-Cárdenas ⁴, Cristina Reátegui-Sokolova ⁵, Mariela Medina-Chinchón ², Francisco Zevallos ⁵, Erika Noriega ⁴, José Alfaro-Lozano ⁴, Jorge Cucho-Venegas ², César Sánchez-Schwartz ², Zoila Rodríguez-Bellido ⁴, Risto Perich-Campos ⁴, Cesar Pastor-Asurza ⁵, Graciela Alarcón ⁶ and Manuel Ugarte-Gil ⁷, ¹Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen, Lima, Lima, Peru, ³Hospital Nacional “Guillermo Almenara Irigoyen” Essalud, Lima., Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶University of Alabama at Birmingham, Birmingham, ⁷Universidad Científica del Sur, Lima, Peru
Background/Purpose: To identify demographic and clinical risk factors for mortality in patients with ANCA-associated vasculitis (AAV) who were followed-up in a Latin-American Tertiary Referral Hospital.Methods:…
Abstract Number: 2624 • 2019 ACR/ARP Annual Meeting
Comparison Between Long-Term and Conventional Rituximab-Maintenance Treatments: Results of a Placebo-Controlled Randomized Trial
Pierre Charles¹, Elodie Perrodeau ², Maxime Samson ³, Bernard Bonnotte ⁴, Mohamed Hamidou ⁵, Christian Agard ⁵, Antoine Huart ⁶, Alexandre Karras ⁷, François Lifermann ⁸, Pascal Godmer ⁹, Pascal Cohen ¹⁰, Catherine Hanrotel-Saliou ¹¹, Nicolas Martin-Silva ¹², Grégory Pugnet ¹³, François Maurier ¹⁴, Jean Sibilia ¹⁵, Pierre-Louis Carron ¹⁶, Pierre Gobert ¹⁷, Nadine Meaux Ruault ¹⁸, Thomas Le Gallou ¹⁹, Stéphane Vinzio ²⁰, Jean-François Viallard ²¹, Eric Hachulla ²², Christine Vinter ², Xavier Puéchal for the French Vasculitis Study Group ¹⁰, Benjamin Terrier ¹⁰, Philippe Ravaud ², Luc Mouthon ¹⁰ and Loic Guillevin ¹⁰, ¹Institut Mutualiste Montsouris, Paris, France, ²APHP, Paris, France, ³CHU Dijon, Dijon, France, ⁴Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ⁵CHU Nantes, Nantes, France, ⁶CHU Toulouse, Toulouse, France, ⁷Paris HEGP, Paris, France, ⁸CH Dax, Dax, France, ⁹CH Bretagne-Atlantique, Vannes, France, ¹⁰National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ¹¹CHU Brest, Brest, France, ¹²CHU Caen, Caen, France, ¹³CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹⁴Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ¹⁵CHU Strasbourg, Strasbourg, France, ¹⁶Grenoble, Grenoble, France, ¹⁷CH Avignon, Avignon, France, ¹⁸CHU Besançon, Besançon, France, ¹⁹CHU Rennes, Rennes, France, ²⁰GHM Grenoble, Grenoble, France, ²¹CHU Bordeaux, Bordeaux, France, ²²Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: MAINRITSAN-trial results1 demonstrated rituximab superiority (500 mg on days 0 and 14, then at months 6, 12 and 18) to azathioprine to maintain remission…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].